EV-103 Cohort H: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible MIBC

EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBCПодробнее

EV-103: EV with pembrolizumab in cisplatin-ineligible urothelial carcinomaПодробнее

EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUCПодробнее

Results of EV 103 | EV-103 Study by Dr. Jonathan RosenbergПодробнее

The role of enfortumab vedotin in earlier lines and stages of urothelial cancer | Arjun BalarПодробнее

Latest EV-103 update further supports enfortumab for untreated advanced UC | Jonathan RosenbergПодробнее

Defining Platinium ineligible | EV-103 Study by Dr. Jonathan RosenbergПодробнее

The future of enfortumab vedotin in different stages bladder cancerПодробнее

EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinomaПодробнее

Enfortumab vedotin in urothelial cancerПодробнее

EV-201, EV-301 and UNITE: enfortumab vedotin in advanced urothelial cancerПодробнее

Phase III VOLGA: durvalumab + tremelimumab + enfortumab vedotin for neoadjuvant MIBCПодробнее

Enfortumab vedotin as treatment for urothelial carcinomasПодробнее

Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinomaПодробнее

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carc...Подробнее

EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancerПодробнее

ESMO Expert Report on antibody drug conjugates in the management of urothelial cancer @ASCO GU 2022Подробнее

Enfortumab Vedotin for Previously-Treated Advanced Urothelial CarcinomaПодробнее

EV-301 update reinforces third-line enfortumab vedotin benefit in advanced UC | Jonathan RosenbergПодробнее